<Research Hypothesis> The dynamics of immune cells by CCRT/Durvalumab will be uncovered. The
combination of Durvalumab with concurrent chemoradiotherapy (CCRT/gemcitabine)) as neoaduvant
treatment in resectable or borderline resectable pancreatic cancer is feasible and
The combination of Durvalumab with cytotoxic chemotherapy (gemcitabine) as an adjuvant
treatment is feasible and efficacious.
<Objectives> To assess the effect of Neoadjuvant CCRT with Gemcitabine/Durvalumab followed by
adjuvant Gemcitabine/Durvalumab in resectable or borderline resectable pancreatic cancer
Efficacy: 2 year-OSR (overall survival rate), disease-free survival, overall survival,
overall response rate (RECIST 1.1, ir response) after neoadjuvant CCRT, disease control
rateEORTC QLQ-C30, the number of immune cells (TIL, macrophage, etc) in resected
Safety: toxicity (CTCAE V), irAE,
To evaluate baseline measures and changes of immune systems and regulations by
neoadjuvant CCRT with gemcitabine/Durvalumab in peripheral blood and tumor tissues
To collect and store DNA from blood (according to ethical procedures) for future
exploratory research into genes/genetic variation that may influence response (ie,
distribution, safety, tolerability and efficacy) to study treatments and or
susceptibility to disease (optional).
Neoplasm of unspecified nature of digestive system,
Islet Ce417ll Cancer,
Digestive System Neoplasms,
cancer of the pancreas,
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.